Elevation Oncology Inc is a biopharmaceutical company focused on developing targeted therapies for patients with genomically defined cancers
The company is dedicated to understanding the unique genetic drivers of these diseases and aims to create innovative treatment options that address unmet medical needs. By leveraging its expertise in precision medicine and oncology, Elevation Oncology works to advance its clinical pipeline, providing hope to patients with rare and challenging cancer types through personalized and effective therapeutic strategies.
Intrigued by the market activity in the middle of the day on Thursday? Uncover the key winners and losers of today's session in our insightful analysis.
Elevation Oncology's ADCs target CLDN18.2 and HER3, with EO-3021 showing promising Phase 1 results and a $6.6 billion TAM in gastric and pancreatic cancers.
Elevation Oncology shares dropped after initial data from the Phase 1 trial of EO-3021 showed a 42.8% objective response rate in patients with advanced solid tumors expressing Claudin 18.2. No Grade 4 or 5 adverse events were reported. The company plans further trial expansion in 2025.
